|Trade names||Desyrel, Trittico, many brand names worldwide|
|By mouth (tablets)|
|Bioavailability||By mouth: 65%|
|Metabolism||Liver (CYP3A4, CYP2D6, CYP1A2?)|
|Onset of action||By mouth: 1 hour (Tmax)|
|Elimination half-life||Trazodone IR: 7 hours|
Trazodone ER: 10 hours
mCPP: 4–14 hours
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||371.87 g·mol−1|
|3D model (JSmol)|
|Melting point||87 °C (189 °F)|
Trazodone, sold under many brand names, is an antidepressant medication. It is used to treat major depressive disorder, anxiety disorders, and, with other medications, alcohol dependence. It is taken by mouth.
Common side-effects include dry mouth, feeling faint, vomiting, and headache. More serious side effects may include suicide, mania, irregular heart rate, and pathologically prolonged erections. It is unclear if use during pregnancy or breastfeeding is safe. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. Trazodone also has sedating effects.
Trazodone was approved for medical use in the United States in 1981. It is available as a generic medication. In 2018, it was the 31st most commonly prescribed medication in the United States, with more than 22 million prescriptions.
Trazodone has the following medical uses:
The primary use of trazodone is the treatment of major depression. Data from open and double-blind trials suggest the antidepressant efficacy of trazodone is comparable to that of amitriptyline, doxepin, and mianserin. Also, trazodone showed anxiolytic properties, low cardiotoxicity, and relatively mild side effects.
Because trazodone has minimal anticholinergic activity, it was especially welcomed as a treatment for geriatric patients with depression when it first became available. Three double-blind studies reported trazodone has antidepressant efficacy similar to that of other antidepressants in geriatric patients. However, a side effect of trazodone, orthostatic hypotension, which may cause dizziness and increase the risk of falling, can have devastating consequences for elderly patients; thus, this side effect, along with sedation, often makes trazodone less acceptable for this population, compared with newer compounds that share its lack of anticholinergic activity but not the rest of its side-effect profile. Still, trazodone is often helpful for geriatric patients with depression who have severe agitation and insomnia.
Trazodone is usually used at a dosage of 150 to 300 mg/day for the treatment of depression. Lower doses have also been used to augment other antidepressants, or when initiating therapy. Higher doses up to 600 mg/day have been used in more severe cases of depression, for instance in hospitalized patients. Trazodone is usually administered multiple times per day, but once-daily administration may be similarly effective.
Low-dose trazodone is used off-label in the treatment of insomnia. Two recent reviews found that trazodone is the second-most prescribed agent for insomnia, though most studies have been in depressed individuals.[additional citation(s) needed] Systematic reviews and meta-analyses published in 2017 and 2018 have found trazodone to be a significantly effective medication for insomnia, both in depressed and non-depressed individuals. Trazodone is used at doses in the range of 25 to 100 mg/day for insomnia. In the past, doses of more than 100 mg/day were also studied.
Other off-label uses
- Complex regional pain syndrome
- Obsessive–compulsive disorder (OCD)
- Alcohol withdrawal
- Schizophrenia as an adjunct to improve negative symptoms.
- Erectile dysfunction
- Female sexual dysfunction
- Veterinary medicine
Because of its lack of anticholinergic side effects, trazodone is especially useful in situations in which antimuscarinic effects are particularly problematic (e.g., in patients with benign prostatic hyperplasia, closed-angle glaucoma, or severe constipation). Trazodone's propensity to cause sedation is a dual-edged sword. For many patients, the relief from agitation, anxiety, and insomnia can be rapid; for other patients, including those individuals with considerable psychomotor retardation and feelings of low energy, therapeutic doses of trazodone may not be tolerable because of sedation. Trazodone elicits orthostatic hypotension in some people, probably as a consequence of α1-adrenergic receptor blockade. The unmasking of bipolar disorder may occur with trazodone and other antidepressants.
Precautions for trazodone include known hypersensitivity to trazodone and under 18 years and combined with other antidepressant medications, it may increase the possibility of suicidal thoughts or actions.
Trazodone has been reported to cause seizures in a small number of patients who took it concurrently with medications to control seizures.
While trazodone is not a true member of the SSRI class of antidepressants, it does still share many properties of the SSRIs, especially the possibility of discontinuation syndrome if the medication is stopped too quickly. Care must, therefore, be taken when coming off the medication, usually by a gradual process of tapering down the dose over a period of time.
Antidepressants may increase the risk of suicidal thoughts and behaviors in children and young adults. Close monitoring for emergence of suicidal thoughts and behaviors is thus recommended.
Since trazodone may impair the mental and/or physical abilities required for performance of potentially hazardous tasks, such as operating an automobile or machinery, the patient should be cautioned not to engage in such activities while impaired. Compared to the reversible MAOI antidepressant drug moclobemide, more impairment of vigilance occurs with trazodone.
Case reports have noted cardiac arrhythmias emerging in relation to trazodone treatment, both in patients with pre-existing mitral valve prolapse and in patients with negative personal and family histories of cardiac disease.
QT prolongation has been reported with trazodone therapy. Arrhythmia identified include isolated PVCs, ventricular couplets, and in two patients short episodes (three to four beats) of ventricular tachycardia. Several post-marketing reports have been made of arrhythmia in trazodone-treated patients who have pre-existing cardiac disease and in some patients who did not have pre-existing cardiac disease. Until the results of prospective studies are available, patients with pre-existing cardiac disease should be closely monitored, particularly for cardiac arrhythmias. Trazodone is not recommended for use during the initial recovery phase of myocardial infarction. Concomitant administration of drugs that prolong the QT interval or that are inhibitors of CYP3A4 may increase the risk of cardiac arrhythmia.
A relatively rare side effect associated with trazodone is priapism, likely due to its antagonism at α-adrenergic receptors. More than 200 cases have been reported, and the manufacturer estimated that the incidence of any abnormal erectile function is about one in 6,000 male patients treated with trazodone. The risk for this side effect appears to be greatest during the first month of treatment at low dosages (i.e. <150 mg/day). Early recognition of any abnormal erectile function is important, including prolonged or inappropriate erections, and should prompt discontinuation of trazodone treatment. Clinical reports have also described trazodone-associated psychosexual side effects in women, including increased libido, priapism of the clitoris, and spontaneous orgasms.
Pregnancy and lactation
There are reported cases of high doses of trazodone precipitating serotonin syndrome. There are also reports of patients taking multiple SSRIs with trazodone and precipitating serotonin syndrome.
Trazodone appears to be relatively safer than TCAs, MAOIs, and a few of the other second-generation antidepressants in overdose situations, especially when it is the only agent taken. Fatalities are rare, and uneventful recoveries have been reported after ingestion of doses as high as 6,000–9,200 mg. In one report, 9 of 294 cases of overdose were fatal, and all nine patients had also taken other central nervous system (CNS) depressants. When trazodone overdoses occur, clinicians should carefully monitor for low blood pressure, a potentially serious toxic effect. In a report of a fatal trazodone overdose, torsades de pointes and complete atrioventricular block developed, along with subsequent multiple organ failure, with a trazodone plasma concentration of 25.4 mg/L on admission.
There is no specific antidote for trazodone. Management of overdosage should, therefore, be symptomatic and supportive. Any person suspected of having taken an overdosage should be evaluated at a hospital as soon as possible. Activated charcoal, and forced diuresis may be useful in facilitating elimination of the drug, gastric lavage has been shown to not be useful unless done during the first hour after intake.
Trazodone is metabolized by several liver enzymes, including CYP3A4, CYP2D6, and CYP1A2. Its active metabolite meta-chlorophenylpiperazine (mCPP) is known to be formed by CYP3A4 and metabolized by CYP2D6. Inhibition or induction of the aforementioned enzymes by various other substances may alter the metabolism of trazodone and/or mCPP, leading to increased and/or decreased blood concentrations. The enzymes in question are known to be inhibited and induced by many medications, herbs, and foods, and as such, trazodone may interact with these substances. Potent CYP3A4 inhibitors such as clarithromycin, erythromycin, fluvoxamine, grapefruit juice, ketoconazole, and ritonavir may lead to increased concentrations of trazodone and decreased concentrations of mCPP, while CYP3A4 inducers like carbamazepine, enzalutamide, phenytoin, phenobarbital, and St. John's wort may result in decreased trazodone concentrations and increased mCPP concentrations. CYP2D6 inhibitors may result in increased concentrations of both trazodone and mCPP while CYP2D6 inducers may decrease their concentrations. Examples of potent CYP2D6 inhibitors include bupropion, cannabidiol, duloxetine, fluoxetine, paroxetine, quinidine, and ritonavir, while CYP2D6 inducers include dexamethasone, glutethimide, and haloperidol. CYP1A2 inhibitors may increase trazodone concentrations while CYP1A2 inducers may decrease trazodone concentrations. Examples of potent CYP1A2 inhibitors include ethinylestradiol (found in hormonal birth control) fluoroquinolones (e.g., ciprofloxacin), fluvoxamine, and St. John's wort, while potent CYP1A2 inducers include phenytoin, rifampin, ritonavir, and tobacco.
A study found that ritonavir, a strong CYP3A4 and CYP2D6 inhibitor and moderate CYP1A2 inducer, increased trazodone peak levels by 1.34-fold, increased area-under-the-curve levels by 2.4-fold, and decreased the clearance of trazodone by 50%. This was associated with adverse effects such as nausea, hypotension, and syncope. Another study found that the strong CYP3A4 inducer carbamazepine reduced concentrations of trazodone by 60 to 74%. The strong CYP2D6 inhibitor thioridazine has been reported to increase concentrations of trazodone by 1.36-fold and concentrations of mCPP by 1.54-fold. On the other hand, CYP2D6 genotype has not been found to predict trazodone or mCPP concentrations with trazodone therapy, although it did correlate with side effects like dizziness and prolonged corrected prolonged corrected QT interval.
Combination of trazodone with selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), or monoamine oxidase inhibitors has a theoretical risk of serotonin syndrome. However, trazodone has been studied in combination with SSRIs and seemed to be safe in this context. On the other hand, cases of excessive sedation and serotonin syndrome have been reported with the combinations of trazodone and fluoxetine or paroxetine. This may be due to combined potentiation of the serotonin system. However, it may also be related to the fact that fluoxetine and paroxetine are strong inhibitors of CYP2D6 and fluoxetine is additionally a weak or moderate inhibitor of CYP3A4. Accordingly, fluoxetine has been reported to result in increased levels of trazodone and mCPP by 1.31- to 1.65-fold and by 2.97- to 3.39-fold, respectively.
Smokers have lower levels of trazodone and higher ratios of mCPP to trazodone. Trazodone levels were 30% lower in smokers and mCPP to trazodone ratio was 1.29-fold higher in smokers, whereas mCPP concentrations were not different between smokers and non-smokers. Smoking is known to induce CYP1A2, and this may be involved in these findings.
|Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site.|
Trazodone is a mixed agonist and antagonist of various serotonin receptors, antagonist of adrenergic receptors, weak histamine H1 receptor antagonist, and weak serotonin reuptake inhibitor. More specifically, it is an antagonist of 5-HT2A and 5-HT2B receptors, a partial agonist of the 5-HT1A receptor, and an antagonist of the α1- and α2-adrenergic receptors. It is also a ligand of the 5-HT2C receptor with lower affinity than for the 5-HT2A receptor. However, it is unknown whether trazodone acts as a full agonist, partial agonist, or antagonist of the 5-HT2C receptor. Trazodone is a 5-HT1A receptor partial agonist similarly to buspirone and tandospirone but with comparatively greater intrinsic activity. A range of weak affinities (Ki) have been reported for trazodone at the human histamine H1 receptor, including 220 nM, 350 nM, 500 nM, and 1,100 nM.
Trazodone has a minor active metabolite known as meta-chlorophenylpiperazine (mCPP), and this metabolite may contribute to some degree to the pharmacological properties of trazodone. In contrast to trazodone, mCPP is an agonist of various serotonin receptors. It has relatively low affinity for α1-adrenergic receptors unlike trazodone, but does high affinity for α2-adrenergic receptors and weak affinity for the H1 receptor. In addition to direct interactions with serotonin receptors, mCPP is a serotonin releasing agent similarly to agents like fenfluramine and MDMA. In contrast to these serotonin releasing agents however, mCPP does not appear to cause long-term serotonin depletion (a property thought to be related to serotonergic neurotoxicity).
Trazodone's 5-HT2A receptor antagonism and weak serotonin reuptake inhibition form the basis of its common label as an antidepressant of the serotonin antagonist and reuptake inhibitor (SARI) type.
Target occupancy studies
Studies have estimated occupancy of target sites by trazodone based on trazodone concentrations in blood and brain and on the affinities of trazodone for the human targets in question. Roughly half of brain 5-HT2A receptors are blocked by 1 mg of trazodone and essentially all 5-HT2A receptors are saturated at 10 mg of trazodone, but the clinically effective hypnotic doses of trazodone are in the 25–100 mg range. The occupancy of the serotonin transporter (SERT) by trazodone is estimated to be 86% at 100 mg/day and 90% at 150 mg/day. Trazodone may almost completely occupy the 5-HT2A and 5-HT2C receptors at doses of 100 to 150 mg/day. Significant occupancy of a number of other sites may also occur. However, another study estimated much lower occupancy of the SERT and 5-HT2A receptors by trazodone.
|Target||Estimated target occupancy|
|50 mg/day||100 mg/day||150 mg/day|
|Very low (<25–33%): NET, DAT, 5-HT1B, 5-HT1E, 5-HT3, 5-HT5A, 5-HT6, β1, β2, D5, H4, mAChRs, nAChRs. Low (<50%): D1, D2. Not determined: α1B, α2B, D3. Note: Another study estimated much lower occupancies.|
Correspondence to clinical effects
This section needs to be updated. The reason given is: Needs to be updated in light of new occupancy studies..(October 2020)
Trazodone may act predominantly as a 5-HT2A receptor antagonist to mediate its therapeutic benefits against anxiety and depression. Its inhibitory effects on serotonin reuptake and 5-HT2C receptors are comparatively weak. In relation to these properties, trazodone does not have similar properties to selective serotonin reuptake inhibitors (SSRIs) and is not particularly associated with increased appetite and weight gain—unlike other 5-HT2C antagonists like mirtazapine. Moderate 5-HT1A partial agonism may contribute to trazodone's antidepressant and anxiolytic actions to some extent as well.
The combined actions of 5-HT2A and 5HT2C receptor antagonism with serotonin reuptake inhibition only occur at moderate to high doses of trazodone. Doses of trazodone lower than those effective for antidepressant action are frequently used for the effective treatment of insomnia. Low doses exploit trazodone's potent actions as a 5-HT2A receptor antagonist, and its properties as an antagonist of H1 and α1-adrenergic receptors, but do not adequately exploit its SERT or 5-HT2C inhibition properties, which are weaker. Since insomnia is one of the most frequent residual symptoms of depression after treatment with an SSRI, a hypnotic is often necessary for patients with a major depressive episode. Not only can a hypnotic potentially relieve the insomnia itself, but treating insomnia in patients with major depression may also increase remission rates due to improvement of other symptoms such as loss of energy and depressed mood. Thus, the ability of low doses of trazodone to improve sleep in depressed patients may be an important mechanism whereby trazodone can augment the efficacy of other antidepressants.
Trazodone's potent α1-adrenergic blockade may cause some side effects like orthostatic hypotension and sedation. Conversely, along with 5-HT2A and H1 receptor antagonism, it may contribute to its efficacy as a hypnotic. Trazodone lacks any affinity for the muscarinic acetylcholine receptors, so does not produce anticholinergic side effects.
mCPP, a non-selective serotonin receptor modulator and serotonin releasing agent, is an active metabolite of trazodone and has been suggested to possibly play a role in its therapeutic benefits. However, research has not supported this hypothesis and mCPP might actually antagonize the efficacy of trazodone as well as produce additional side effects.
Trazodone is well-absorbed after oral administration. Its bioavailability is 65 to 80%. Peak blood levels of trazodone occur 1 to 2 hours after ingestion and peak levels of the metabolite mCPP occur after 2 to 4 hours. Absorption is somewhat delayed and enhanced by food.
The metabolic pathways involved in the metabolism are not well-characterized. In any case, the cytochrome P450 enzymes CYP3A4, CYP2D6, and CYP1A2 may all be involved to varying extents. Trazodone is known to be extensively metabolized by the liver via hydroxylation, N-oxidation, and N-dealkylation. Several metabolites of trazodone have been identified, including a dihydrodiol metabolite (via hydroxylation), a metabolite hydroxylated at the para position of the meta-chlorophenyl ring (via CYP2D6), oxotriazolepyridinepropionic acid (TPA) and mCPP (both via N-dealkylation of the piperazinyl nitrogen mediated by CYP3A4), and a metabolite formed by N-oxidation of the piperazinyl nitrogen. CYP1A2, CYP2D6, and CYP3A4 genotypes all do not seem to predict concentrations of trazodone or mCPP. In any case, there are large interindividual variations in the metabolism of trazodone. In addition, poor metabolizers of dextromethorphan, a CYP2D6 substrate, eliminate mCPP more slowly and have higher concentrations of mCPP than do extensive metabolizers.
mCPP is formed from trazodone by CYP3A4 and is metabolized via hydroxylation by CYP2D6 (to a para-hydroxylated metabolite). It may contribute to the pharmacological actions of trazodone. mCPP levels are only 10% of those of trazodone during therapy with trazodone, but is nonetheless present at concentrations known to produce psychic and physical effects in humans when mCPP has been administered alone. In any case, the actions of trazodone, such as its serotonin antagonism, might partially overwhelm those of mCPP. As a consequence of the production of mCPP as a metabolite, patients administered trazodone may test positive on EMIT II urine tests for the presence of MDMA ("ecstasy").
The mean blood elimination half-life of trazodone is biphasic: the first phase's half-life is 3 to 6 hours, and the following phase's half-life is 5 to 9 hours. The elimination half-life of mCPP is 4 to 14 hours and is longer than that of trazodone. Metabolites are conjugated to gluconic acid or glutathione and around 70 to 75% of 14C-labelled trazodone was found to be excreted in the urine within 72 hours. The remaining drug and its metabolites are excreted in the faeces via biliary elimination. Less than 1% of the drug is excreted in its unchanged form. After an oral dose of trazodone, it was found to be excreted 20% in the urine as TPA and conjugates, 9% as the dihydrodiol metabolite, and less than 1% as unconjugated mCPP. mCPP is glucuronidated and sulfated similarly to other trazodone metabolites.
Trazodone was developed in Italy, in the 1960s, by Angelini Research Laboratories as a second-generation antidepressant. It was developed according to the mental pain hypothesis, which was postulated from studying patients and which proposes that major depression is associated with a decreased pain threshold. In sharp contrast to most other antidepressants available at the time of its development, trazodone showed minimal effects on muscarinic cholinergic receptors. Trazodone was patented and marketed in many countries all over the world. It was approved by the Food and Drug Administration (FDA) in 1981 and was the first non-tricyclic or MAOI antidepressant approved in the US.
Society and culture
Trazodone has been marketed under a large number of brand names throughout the world. Major brand names include Desyrel (worldwide), Donaren (Brazil), Molipaxin (Ireland, United Kingdom), Oleptro (United States), Trazorel (Canada), and Trittico (worldwide).
- "Trazodone". Drugs.com. Retrieved 9 February 2019.
- Hubbard JR, Martin PR (2001). Substance Abuse in the Mentally and Physically Disabled. CRC Press. p. 26. ISBN 9780824744977.
- Truven Health Analytics, Inc. DrugPoint System (Internet) [cited 2013 Oct 1]. Greenwood Village, CO: Thomsen Healthcare; 2013.[failed verification]
- "Trazodone". DrugBank. Retrieved 7 June 2015.
- Preskorn SH, Stanga CY, Feighner JP, Ross J (6 December 2012). Antidepressants: Past, Present and Future. Springer Science & Business Media. pp. 68–. ISBN 978-3-642-18500-7.
- "MicroMedex DrugPoints - Trazodone". Pharmacy Choice. Retrieved 20 April 2017.
- Rotzinger S, Bourin M, Akimoto Y, Coutts RT, Baker GB (August 1999). "Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine". Cell Mol Neurobiol. 19 (4): 427–42. doi:10.1023/a:1006953923305. PMID 10379419. S2CID 19585113.
- Schatzberg AF, Nemeroff CB (2017). The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition. American Psychiatric Pub. pp. 460–. ISBN 978-1-58562-523-9.
- Cuomo A, Ballerini A, Bruni AC, Decina P, Di Sciascio G, Fiorentini A, Scaglione F, Vampini C, Fagiolini A (2019). "Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice". Riv Psichiatr. 54 (4): 137–149. doi:10.1708/3202.31796. PMID 31379379.
- Mittur A (March 2011). "Trazodone: properties and utility in multiple disorders". Expert Rev Clin Pharmacol. 4 (2): 181–96. doi:10.1586/ecp.10.138. PMID 22115401. S2CID 6068710.
- Rotzinger S, Fang J, Coutts RT, Baker GB (December 1998). "Human CYP2D6 and metabolism of m-chlorophenylpiperazine". Biological Psychiatry. 44 (11): 1185–91. doi:10.1016/S0006-3223(97)00483-6. PMID 9836023. S2CID 45097940.
- Lemke TL, Williams DA (2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. p. 615. ISBN 9781609133450.
- "Trazodone Hydrochloride". The American Society of Health-System Pharmacists. Retrieved 8 January 2018.
- "Trazodone Use During Pregnancy". Drugs.com. Retrieved 7 January 2018.
- Stahl SM (2008). Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press. p. 567. ISBN 9780521857024.
- Lemke TL, Williams DA (2008). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. p. 586. ISBN 9780781768795.
- British national formulary: BNF 69 (69th ed.). British Medical Association. 2015. pp. 257–258. ISBN 9780857111562.
- "The Top 300 of 2021". ClinCalc. Retrieved 18 February 2021.
- "Trazodone Hydrochloride - Drug Usage Statistics". ClinCalc. Retrieved 18 February 2021.
- "Desyrel – FDA Prescribing Information". Drugs.com. Retrieved 4 June 2015.
- British National Formulary (BNF) 65. London, UK: Pharmaceutical Press. 2013. p. 247. ISBN 9780857110848.
- Nierenberg AA, Adler LA, Peselow E, Zornberg G, Rosenthal M (July 1994). "Trazodone for antidepressant-associated insomnia". Am J Psychiatry. 151 (7): 1069–72. doi:10.1176/ajp.151.7.1069. PMID 8010365.
- Schatzberg, AF; Nemeroff, CB, eds. (2009). Textbook of Psychopharmacology (4th ed.). Washington, D.C.: American Psychiatric Publishing. ISBN 978-1-58562-309-9.
- Fagiolini A, Comandini A, Catena Dell'Osso M, Kasper S (2012). "Rediscovering trazodone for the treatment of major depressive disorder". CNS Drugs. 26 (12): 1033–49. doi:10.1007/s40263-012-0010-5. PMC 3693429. PMID 23192413.
- Haria M, Fitton A, McTavish D (April 1994). "Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders". Drugs Aging. 4 (4): 331–55. doi:10.2165/00002512-199404040-00006. PMID 8019056.
- Fabre LF (September 1990). "Trazodone dosing regimen: experience with single daily administration". J Clin Psychiatry. 51 Suppl: 23–6. PMID 2211561.
- Bossini L, Coluccia A, Casolaro I, Benbow J, Amodeo G, De Giorgi R, Fagiolini A (2015). "Off-Label Trazodone Prescription: Evidence, Benefits and Risks". Curr Pharm Des. 21 (23): 3343–51. doi:10.2174/1381612821666150619092236. PMID 26088119.
- Jaffer KY, Chang T, Vanle B, Dang J, Steiner AJ, Loera N, et al. (1 August 2017). "Trazodone for Insomnia: A Systematic Review". Innovations in Clinical Neuroscience. 14 (7–8): 24–34. PMC 5842888. PMID 29552421.
- Yi XY, Ni SF, Ghadami MR, Meng HQ, Chen MY, Kuang L, Zhang YQ, Zhang L, Zhou XY (May 2018). "Trazodone for the treatment of insomnia: a meta-analysis of randomized placebo-controlled trials". Sleep Med. 45: 25–32. doi:10.1016/j.sleep.2018.01.010. PMID 29680424.
- Stahl SM (October 2009). "Mechanism of action of trazodone: a multifunctional drug". CNS Spectrums. 14 (10): 536–46. doi:10.1017/s1092852900024020. PMID 20095366. S2CID 2977125.
- "Understanding the Pharmacologic Therapy for Complex Regional Pain Syndrome: Pharmacologic Therapy". Medscape.com. Retrieved 14 March 2014.
- Prasad A (February 1985). "Efficacy of trazodone as an anti obsessional agent". Pharmacol. Biochem. Behav. 22 (2): 347–8. doi:10.1016/0091-3057(85)90403-4. PMID 3983224. S2CID 19495001.
- Roccatagliata G, Albano C, Maffini M, Farelli S (1980). "Alcohol withdrawal syndrome: treatment with trazodone". Int Pharmacopsychiatry. 15 (2): 105–10. doi:10.1159/000468420. PMID 6108298.
- Le Bon O, Murphy JR, Staner L, Hoffmann G, Kormoss N, Kentos M, Dupont P, Lion K, Pelc I, Verbanck P (August 2003). "Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations". J Clin Psychopharmacol. 23 (4): 377–83. doi:10.1097/01.jcp.0000085411.08426.d3. PMID 12920414. S2CID 33686593.
- Borras L, de Timary P, Constant EL, Huguelet P, Eytan A (November 2006). "Successful treatment of alcohol withdrawal with trazodone". Pharmacopsychiatry. 39 (6): 232. doi:10.1055/s-2006-951385. PMID 17124647.
- Singh SP, Singh V, Kar N, Chan K (September 2010). "Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis". Br J Psychiatry. 197 (3): 174–9. doi:10.1192/bjp.bp.109.067710. PMID 20807960.
- Fink HA, MacDonald R, Rutks IR, Wilt TJ (September 2003). "Trazodone for erectile dysfunction: a systematic review and meta-analysis". BJU Int. 92 (4): 441–6. doi:10.1046/j.1464-410X.2003.04358.x. PMID 12930437. S2CID 7499389.
- Pyke RE (April 2020). "Trazodone in Sexual Medicine: Underused and Overdosed?". Sex Med Rev. 8 (2): 206–216. doi:10.1016/j.sxmr.2018.08.003. PMID 30342856.
- "Trazodone for Dogs: Dosage, Side Effects, and Alternatives". Relievet. Retrieved 3 September 2020.
- "Trazodone - FDA prescribing information, side effects and uses".
- "Desyrel (Trazodone Hydrochloride): Side Effects, Interactions, Warning, Dosage & Uses".
- "Oleptro (trazodone hydrochloride) extended-release tablets". Pharmacy and Therapeutics. 36 (2): 2–18. 2011. ISSN 1052-1372. PMC 3059557. PMID 21431085.
- "Trazodone (Oral Route) Proper Use - Mayo Clinic". www.mayoclinic.org. Retrieved 11 February 2020.
- Malhi GS (November 2015). "Antidepressants in bipolar depression: yes, no, maybe?". Evid Based Ment Health. 18 (4): 100–2. doi:10.1136/eb-2015-102229. PMID 26459471.
- "Webmd.com". Webmd.com. Retrieved 14 March 2014.
- Warner CH, Bobo W, Warner C, Reid S, Rachal J (August 2006). "Antidepressant discontinuation syndrome". Am Fam Physician. 74 (3): 449–56. PMID 16913164.
- "FDA - Trazodone Prescribing Information" (PDF).
- Wesnes KA, Simpson PM, Christmas L, Anand R, McClelland GR (1989). "The effects of moclobemide on cognition". J. Neural Transm. Suppl. 28: 91–102. PMID 2677245.
- Schatzberg, AF; Nemeroff, CB, eds. (2009). Textbook of Psychopharmacology (4th ed.). Washington, D.C.: American Psychiatric Publishing. ISBN 978-1-58562-309-9.
- "Trazodone PRODUCT MONOGRAPH" (PDF). 2015.
- "HIGHLIGHTS OF PRESCRIBING INFORMATION" (PDF). U.S. Food and Drug Administration. 2017.
- Abber JC, Lue TF, Luo JA, Juenemann KP, Tanagho EA (May 1987). "Priapism induced by chlorpromazine and trazodone: mechanism of action". J. Urol. 137 (5): 1039–42. doi:10.1016/s0022-5347(17)44355-2. PMID 3573170.
- Battaglia C, Venturoli S (October 2009). "Persistent genital arousal disorder and trazodone. Morphometric and vascular modifications of the clitoris. A case report". J Sex Med. 6 (10): 2896–900. doi:10.1111/j.1743-6109.2009.01418.x. PMID 19674253.
- Kalgutkar AS, Henne KR, Lame ME, Vaz AD, Collin C, Soglia JR, Zhao SX, Hop CE (June 2005). "Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4". Chem. Biol. Interact. 155 (1–2): 10–20. doi:10.1016/j.cbi.2005.03.036. PMID 15978881.
- Otani K, Yasui N, Kaneko S, Ishida M, Ohkubo T, Osanai T, Sugawara K, Fukushima Y (June 1995). "Trazodone treatment increases plasma prolactin concentrations in depressed patients". Int Clin Psychopharmacol. 10 (2): 115–7. doi:10.1097/00004850-199506000-00009. PMID 7673654. S2CID 41490922.
- Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D, Johnson Y, Koren G (March 2003). "A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy". Can J Psychiatry. 48 (2): 106–10. doi:10.1177/070674370304800207. PMID 12655908.
- Verbeeck RK, Ross SG, McKenna EA (September 1986). "Excretion of trazodone in breast milk". Br J Clin Pharmacol. 22 (3): 367–70. doi:10.1111/j.1365-2125.1986.tb02903.x. PMC 1401139. PMID 3768252.
- Cushing TA (24 April 2018). "Selective Serotonin Reuptake Inhibitor Toxicity". Medscape. WebMD LLC. Retrieved 22 December 2018.
- Martínez MA, Ballesteros S, Sánchez de la Torre C, Almarza E (2005). "Investigation of a fatality due to trazodone poisoning: case report and literature review". J Anal Toxicol. 29 (4): 262–8. doi:10.1093/jat/29.4.262. PMID 15975258.
- de Meester A, Carbutti G, Gabriel L, Jacques JM (2001). "Fatal overdose with trazodone: case report and literature review". Acta Clin Belg. 56 (4): 258–61. doi:10.1179/acb.2001.038. PMID 11603256. S2CID 21487479.
- Rakel RE (1987). "The greater safety of trazodone over tricyclic antidepressant agents: 5-year experience in the United States". Psychopathology. 20 (Suppl 1): 57–63. doi:10.1159/000284524. PMID 3321131.
- Rotzinger S, Fang J, Baker GB (June 1998). "Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources". Drug Metabolism and Disposition. 26 (6): 572–5. PMID 9616194.
- Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Ishida M, Mihara K, Kondo T, Sugawara K, Fukushima Y (August 1995). "Inhibition of trazodone metabolism by thioridazine in humans". Ther Drug Monit. 17 (4): 333–5. doi:10.1097/00007691-199508000-00003. PMID 7482685. S2CID 1979283.
- Khouzam HR (2017). "A review of trazodone use in psychiatric and medical conditions". Postgrad Med. 129 (1): 140–148. doi:10.1080/00325481.2017.1249265. PMID 27744763. S2CID 205452630.
- Mihara K, Otani K, Suzuki A, Yasui N, Nakano H, Meng X, Ohkubo T, Nagasaki T, Kaneko S, Tsuchida S, Sugawara K, Gonzalez FJ (September 1997). "Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine". Psychopharmacology (Berl). 133 (1): 95–8. doi:10.1007/s002130050376. PMID 9335086. S2CID 11521715.
- Saiz-Rodríguez M, Belmonte C, Derqui-Fernández N, Cabaleiro T, Román M, Ochoa D, Talegón M, Ovejero-Benito MC, Abad-Santos F (November 2017). "Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety". Pharmacogenomics. 18 (16): 1491–1502. doi:10.2217/pgs-2017-0116. PMID 29061081.
- Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, Isoherranen N (June 2014). "Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4". Clin Pharmacol Ther. 95 (6): 653–62. doi:10.1038/clpt.2014.50. PMC 4029899. PMID 24569517.
- Maes, M; Westenberg, H; Vandoolaeghe, E; Demedts, P; Wauters, A; Neels, H; Meltzer, HY (October 1997). "Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine". Journal of Clinical Psychopharmacology. 17 (5): 358–64. doi:10.1097/00004714-199710000-00004. PMID 9315986. Archived from the original on 31 October 1997. Lay summary.CS1 maint: uses authors parameter (link)
- Ishida M, Otani K, Kaneko S, Ohkubo T, Osanai T, Yasui N, Mihara K, Higuchi H, Sugawara K (September 1995). "Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine". Int Clin Psychopharmacol. 10 (3): 143–6. doi:10.1097/00004850-199510030-00002. PMID 8675966.
- Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
- Roth, BL; Driscol, J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 25 May 2018.
- Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997). "Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites". J. Pharmacol. Exp. Ther. 283 (3): 1305–22. PMID 9400006.
- Tatsumi M, Groshan K, Blakely RD, Richelson E (1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". Eur. J. Pharmacol. 340 (2–3): 249–58. doi:10.1016/s0014-2999(97)01393-9. PMID 9537821.
- Cusack B, Nelson A, Richelson E (1994). "Binding of antidepressants to human brain receptors: focus on newer generation compounds". Psychopharmacology. 114 (4): 559–65. doi:10.1007/bf02244985. PMID 7855217. S2CID 21236268.
- Hamik A, Peroutka SJ (1989). "1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain". Biol. Psychiatry. 25 (5): 569–75. doi:10.1016/0006-3223(89)90217-5. PMID 2537663. S2CID 46730665.
- Boess FG, Martin IL (1994). "Molecular biology of 5-HT receptors". Neuropharmacology. 33 (3–4): 275–317. doi:10.1016/0028-3908(94)90059-0. PMID 7984267. S2CID 35553281.
- Hamblin MW, Metcalf MA (1991). "Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor". Mol. Pharmacol. 40 (2): 143–8. PMID 1652050.
- Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M (2004). "Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors". Naunyn Schmiedebergs Arch. Pharmacol. 370 (2): 114–23. doi:10.1007/s00210-004-0951-4. PMID 15322733. S2CID 8938111.
- Bonhaus DW, Bach C, DeSouza A, Salazar FH, Matsuoka BD, Zuppan P, Chan HW, Eglen RM (1995). "The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors". Br. J. Pharmacol. 115 (4): 622–8. doi:10.1111/j.1476-5381.1995.tb14977.x. PMC 1908489. PMID 7582481.
- Rothman RB, Baumann MH (2009). "Serotonergic drugs and valvular heart disease". Expert Opin Drug Saf. 8 (3): 317–29. doi:10.1517/14740330902931524. PMC 2695569. PMID 19505264.
- Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL (2000). "Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications". Circulation. 102 (23): 2836–41. doi:10.1161/01.cir.102.23.2836. PMID 11104741.
- Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ (1999). "Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells". Br. J. Pharmacol. 128 (1): 13–20. doi:10.1038/sj.bjp.0702751. PMC 1571597. PMID 10498829.
- Bentley JM, Adams DR, Bebbington D, Benwell KR, Bickerdike MJ, Davidson JE, Dawson CE, Dourish CT, Duncton MA, Gaur S, George AR, Giles PR, Hamlyn RJ, Kennett GA, Knight AR, Malcolm CS, Mansell HL, Misra A, Monck NJ, Pratt RM, Quirk K, Roffey JR, Vickers SP, Cliffe IA (2004). "Indoline derivatives as 5-HT(2C) receptor agonists". Bioorg. Med. Chem. Lett. 14 (9): 2367–70. doi:10.1016/j.bmcl.2003.05.001. PMID 15081042.
- Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeeley PM, Szczepanski K, Fontana DJ, Trinh J, Rocha CL, Dawson MW, Flippin LA, Eglen RM (1997). "RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist". Neuropharmacology. 36 (4–5): 621–9. doi:10.1016/s0028-3908(97)00049-x. PMID 9225287. S2CID 24930608.
- Richelson E, Nelson A (1984). "Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro". J. Pharmacol. Exp. Ther. 230 (1): 94–102. PMID 6086881.
- Stanton T, Bolden-Watson C, Cusack B, Richelson E (1993). "Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics". Biochem. Pharmacol. 45 (11): 2352–4. doi:10.1016/0006-2952(93)90211-e. PMID 8100134.
- Raffa RB, Shank RP, Vaught JL (1992). "Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity". Psychopharmacology. 108 (3): 320–6. doi:10.1007/BF02245118. PMID 1387963. S2CID 24965789.
- Odagaki Y, Toyoshima R, Yamauchi T (May 2005). "Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding". J. Psychopharmacol. (Oxford). 19 (3): 235–41. doi:10.1177/0269881105051526. PMID 15888508. S2CID 27389008.
- Krystal AD, Richelson E, Roth T (2013). "Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications". Sleep Med Rev. 17 (4): 263–72. doi:10.1016/j.smrv.2012.08.001. PMID 23357028.
- Lemke TL, Williams DA (2008). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 586–. ISBN 978-0-7817-6879-5.
- Kahn RS, Wetzler S (1991). "m-Chlorophenylpiperazine as a probe of serotonin function". Biol. Psychiatry. 30 (11): 1139–66. doi:10.1016/0006-3223(91)90184-n. PMID 1663792. S2CID 13007057.
- Melzacka M, Rurak A, Vetulani J (1980). "Preliminary study of the biotransformation of two new drugs, trazodone and etoperidone". Polish Journal of Pharmacology and Pharmacy. 32 (4): 551–6. PMID 7255270.
- Fong MH, Garattini S, Caccia S (October 1982). "1-m-Chlorophenylpiperazine is an active metabolite common to the psychotropic drugs trazodone, etoperidone and mepiprazole". The Journal of Pharmacy and Pharmacology. 34 (10): 674–5. doi:10.1111/j.2042-7158.1982.tb04701.x. PMID 6128394. S2CID 44968564.
- Settimo L, Taylor D (January 2018). "Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets". J Psychopharmacol. 32 (1): 96–104. doi:10.1177/0269881117742101. PMID 29332554. S2CID 28804036.
- Marek GJ, McDougle CJ, Price LH, Seiden LS (1992). "A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action". Psychopharmacology. 109 (1–2): 2–11. doi:10.1007/BF02245475. PMID 1365657. S2CID 25140746.
- Vanina Y, Podolskaya A, Sedky K, Shahab H, Siddiqui A, Munshi F, Lippmann S (July 2002). "Body weight changes associated with psychopharmacology". Psychiatr Serv. 53 (7): 842–7. doi:10.1176/appi.ps.53.7.842. PMID 12096167.
- Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, et al. (January 2010). "Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis". CNS Drugs. 24 (1): 35–53. doi:10.2165/11319480-000000000-00000. PMID 20030418. S2CID 7459081.
- Kinney GG, Griffith JC, Hudzik TJ (July 1998). "Antidepressant-like effects of 5-hydroxytryptamine1A receptor agonists on operant responding under a response duration differentiation schedule". Behav Pharmacol. 9 (4): 309–18. doi:10.1097/00008877-199807000-00002. PMID 10065919.
- Stahl, S.M. (2013). Stahl's Essential Psychopharmacology (4th ed.). Cambridge University Press. ISBN 978-1107686465.
- Asayesh K (December 1986). "Combination of trazodone and phenothiazines: a possible additive hypotensive effect". Canadian Journal of Psychiatry. 31 (9): 857–8. doi:10.1177/070674378603100913. PMID 3802006. S2CID 43202340.
- Mihara K, Yasui-Furukori N, Kondo T, Ishida M, Ono S, Ohkubo T, et al. (August 2002). "Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients". Therapeutic Drug Monitoring. 24 (4): 563–6. doi:10.1097/00007691-200208000-00016. PMID 12142643. S2CID 25709000.
- Li AA, Marek GJ, Hand TH, Seiden LS (February 1990). "Antidepressant-like effects of trazodone on a behavioral screen are mediated by trazodone, not the metabolite m-chlorophenylpiperazine". European Journal of Pharmacology. 177 (3): 137–44. doi:10.1016/0014-2999(90)90263-6. PMID 2311675.
- Vetulani J, Sansone M, Baran L, Hano J (1984). "Opposite action of m-chlorophenylpiperazine on avoidance depression induced by trazodone and pimozide in CD-1 mice". Psychopharmacology. 83 (2): 166–8. doi:10.1007/BF00429728. PMID 6431467. S2CID 38913696.
- Kast RE (2009). "Trazodone generates m-CPP: in 2008 risks from m-CPP might outweigh benefits of trazodone". The World Journal of Biological Psychiatry. 10 (4 Pt 2): 682–5. doi:10.1080/15622970902836022. PMID 19384678. S2CID 901077.
- Workman EA, Tellian F, Short D (May 1992). "Trazodone induction of migraine headache through mCPP". The American Journal of Psychiatry. 149 (5): 712b–712. doi:10.1176/ajp.149.5.712b. PMID 1575270.
- "Trazodone". www.drugbank.ca. Retrieved 31 January 2019.
- Mihara K, Kondo T, Suzuki A, Yasui-Furukori N, Ono S, Otani K, Kaneko S (May 2001). "Effects of genetic polymorphism of CYP1A2 inducibility on the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine in depressed Japanese patients". Pharmacol Toxicol. 88 (5): 267–70. doi:10.1034/j.1600-0773.2001.d01-115.x. PMID 11393588.
- Garattini S (1985). "Active drug metabolites. An overview of their relevance in clinical pharmacokinetics". Clinical Pharmacokinetics. 10 (3): 216–27. doi:10.2165/00003088-198510030-00002. PMID 2861928. S2CID 21305772.
- Vaz RJ, Klabunde T (9 April 2008). Antitargets: Prediction and Prevention of Drug Side Effects. John Wiley & Sons. pp. 149–. ISBN 978-3-527-62147-7.
- Logan BK, Costantino AG, Rieders EF, Sanders D (November 2010). "Trazodone, meta-chlorophenylpiperazine (an hallucinogenic drug and trazodone metabolite), and the hallucinogen trifluoromethylphenylpiperazine cross-react with the EMIT®II ecstasy immunoassay in urine". J Anal Toxicol. 34 (9): 587–9. doi:10.1093/jat/34.9.587. PMID 21073812.
- Jauch R, Kopitar Z, Prox A, Zimmer A (1976). "[Pharmacokinetics and metabolism of trazodone in man (author's transl)]". Arzneimittel-Forschung (in German). 26 (11): 2084–9. PMID 1037253.
- Akritopoulou-Zanze I (2012). "6. Arylpiperazine-Based 5-HT1A Receptor Partial Agonists and 5-HT2A Antagonists for the Treatment of Autism, Depression, Anxiety, Psychosis, and Schizophrenia". In Dinges J, Lamberth C (eds.). Bioactive heterocyclic compound classes pharmaceuticals. Weinheim: Wiley-VCH. ISBN 9783527664450.
- Dörwald, Florencioa Zaragoza, ed. (2012). "46. Arylalkylamines". Lead optimization for medicinal chemists : pharmacokinetic properties of functional groups and organic compounds. Weinheim: Wiley-VCH. ISBN 9783527645640.
- Gorecki DK, Verbeeck RK (1987). "Trazondone Hydrochloride". In Forey K (ed.). Profiles of Drug Substances, Excipients and Related Methodology Vol. 16. Academic Press. p. 695. ISBN 9780080861111.
- Wegener G (30 March 2016). "Ban & Silvestrini's Trazodone". inhn.org. Retrieved 4 June 2017.
- Silvestrini B (1989). "Trazodone: from the mental pain to the "dys-stress" hypothesis of depression". Clin Neuropharmacol. 12 (Suppl 1): S4–10. doi:10.1097/00002826-198901001-00002. PMID 2568177. S2CID 34798378.
- "Trazodone: Common sleep drug is little-known antidepressant - Consumer Reports". Consumer Reports. August 2015.
- Eisen MS, Taylor DB, Riblet LA (2012). "Atypical Psychotropic Agents". In Williams M, Malick JB (eds.). Drug Discovery and Development. Springer Science & Business Media. p. 388. ISBN 9781461248286.
- Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. ISBN 978-1-4757-2085-3.
- Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 1050–1052. ISBN 978-3-88763-075-1.
- Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 279–. ISBN 978-94-011-4439-1.
- "Trazodone". Drugs.com.